Biovie Inc (BIVI) Stock Price, Quote & News

Company Profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as fo...

Industry: Biotechnology

Sector: Healthcare

Phone: 775 888 3162

Website: bioviepharma.com

Address:

680 W. Nye Lane, Suite 204, Carson City, United States

CalculatedSwing Oct. 27 at 9:33 PM

$NNVC coming again soon. $GLMD $BIVI $GFAI $CORZ

0 · Reply

Tumble51 Oct. 21 at 10:47 AM

$ACAD $BIVI $CUE $INMB $KPTI kryptonite here is Choung !!! The CEO

0 · Reply

Tumble51 Oct. 21 at 10:46 AM

$BIVI this clown. USA be a relative of TRUMP Eggs will go down Gas will go down Federal employees will be paid , hahahaha

0 · Reply

TJ12000 Oct. 20 at 10:16 PM

$BIVI 19cent turd 💩 #snake oil scam

0 · Reply

Sensore Oct. 20 at 5:18 PM

$BIVI ..

0 · Reply

toccoc Oct. 20 at 2:13 AM

0 · Reply

Sensore Oct. 17 at 11:16 AM

$BIVI ..

0 · Reply

Dipshit101 Oct. 17 at 5:21 AM

$BIVI love all the “Bullish” remarks, sadly they are all wrong, I read them for entertainment Some people just want to be keyboard warriors. Post proof of remark posted Please

0 · Reply

Christinapookie Oct. 15 at 2:19 PM

$BIVI 😳 I saw that…..hopefully news soon

0 · Reply

Tradebait88 Oct. 15 at 1:59 PM

$BIVI we are out of the downward wedge, just needs news

1 · Reply

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 8, 2025, 6:56 PM EDT - 19 days ago

BioVie Inc. - Special Call

Sep 26, 2025, 8:00 AM EDT - 4 weeks ago

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

Aug 13, 2025, 4:05 PM EDT - 2 months ago

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

Aug 7, 2025, 8:43 PM EDT - 2 months ago

BioVie Inc. Announces Pricing of $12 Million Public Offering

Jul 24, 2025, 8:00 AM EDT - 3 months ago

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

Jul 22, 2025, 8:00 AM EDT - 3 months ago

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

Jun 26, 2025, 8:00 AM EDT - 4 months ago

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Jun 24, 2025, 4:05 PM EDT - 4 months ago

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

May 14, 2025, 7:30 AM EDT - 5 months ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

Mar 27, 2025, 8:00 AM EDT - 7 months ago

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

Jan 26, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Shareholders to Inquire about Securities Investigation

Jan 22, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Shareholders to Connect

Jan 19, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Shareholders to Reach Out

Jan 15, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Shareholders to Learn More About the Investigation

Jan 12, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Investors to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 10 months ago

BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 5, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Investors to Connect

Jan 2, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Stockholders to Inquire about Securities Investigation

Dec 24, 2024, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Investors to Reach Out

Dec 22, 2024, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Stockholders to Reach Out

Dec 18, 2024, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Stockholders to Connect

Dec 15, 2024, 10:00 AM EST - 11 months ago

BioVie Inc. (BIVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Dec 11, 2024, 2:00 PM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Stockholders to Learn More About the Investigation

Oct 28, 2024, 4:10 PM EDT - 1 year ago

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 3:13 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 24, 2024, 4:10 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

Oct 23, 2024, 3:24 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 15, 2024, 8:00 AM EDT - 1 year ago

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

Oct 11, 2024, 9:00 AM EDT - 1 year ago

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

Sep 25, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Public Offering

Sep 24, 2024, 2:08 PM EDT - 1 year ago

Crude Oil Gains Over 1%; BioVie Shares Plunge

Sep 23, 2024, 10:26 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Public Offering

Sep 23, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Proposed Public Offering

Sep 16, 2024, 8:00 AM EDT - 1 year ago

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 3, 2024, 8:00 AM EDT - 1 year ago

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Aug 27, 2024, 8:45 AM EDT - 1 year ago

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Aug 8, 2024, 6:00 AM EDT - 1 year ago

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

Aug 6, 2024, 4:40 PM EDT - 1 year ago

BioVie Inc. Announces Reverse Stock Split

Jul 5, 2024, 9:00 AM EDT - 1 year ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Jun 21, 2024, 9:00 AM EDT - 1 year ago

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MOB

Jun 20, 2024, 8:00 AM EDT - 1 year ago

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Jun 12, 2024, 8:24 AM EDT - 1 year ago

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

May 22, 2024, 8:00 AM EDT - 1 year ago

BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients

Apr 29, 2024, 8:00 AM EDT - 1 year ago

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Apr 25, 2024, 8:00 AM EDT - 1 year ago

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints

Apr 18, 2024, 8:00 AM EDT - 1 year ago

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

Apr 12, 2024, 9:00 AM EDT - 1 year ago

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

Mar 26, 2024, 10:30 AM EDT - 1 year ago

Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation

CalculatedSwing Oct. 27 at 9:33 PM

$NNVC coming again soon. $GLMD $BIVI $GFAI $CORZ

0 · Reply

Tumble51 Oct. 21 at 10:47 AM

$ACAD $BIVI $CUE $INMB $KPTI kryptonite here is Choung !!! The CEO

0 · Reply

Tumble51 Oct. 21 at 10:46 AM

$BIVI this clown. USA be a relative of TRUMP Eggs will go down Gas will go down Federal employees will be paid , hahahaha

0 · Reply

TJ12000 Oct. 20 at 10:16 PM

$BIVI 19cent turd 💩 #snake oil scam

0 · Reply

Sensore Oct. 20 at 5:18 PM

$BIVI ..

0 · Reply

toccoc Oct. 20 at 2:13 AM

0 · Reply

Sensore Oct. 17 at 11:16 AM

$BIVI ..

0 · Reply

Dipshit101 Oct. 17 at 5:21 AM

$BIVI love all the “Bullish” remarks, sadly they are all wrong, I read them for entertainment Some people just want to be keyboard warriors. Post proof of remark posted Please

0 · Reply

Christinapookie Oct. 15 at 2:19 PM

$BIVI 😳 I saw that…..hopefully news soon

0 · Reply

Tradebait88 Oct. 15 at 1:59 PM

$BIVI we are out of the downward wedge, just needs news

1 · Reply

Thorilium Oct. 15 at 6:06 AM

$BIVI after two r/s year after year this stands at 2? hmmm

1 · Reply

CalculatedSwing Oct. 15 at 1:14 AM

$BIVI 🚀 $BIVI is primed for liftoff! Phase 2b Parkinson's data incoming + liver Fast Track = massive catalysts ahead. Low float bio with 500% potential—don't sleep! Watching peers $CUE $INMB $ACAD $KPTI for sector rotation. #Biotech #BIVI

1 · Reply

mazzystar1 Oct. 14 at 1:18 PM

$CYDY Thorilium is lying to you about CYDY... he stated that "CYDY is however also nearing approval potential and will break out huge"... CYDY has NOT completed a clinical trial in FOUR YEARS (they had an FDA hold in place for two years)... since the hold was lifted a year and a half ago, CYDY is only running ONE clinical trial and it started about four months ago (they have financial issues - read the 10-Q)... CYDY is having problems getting investigator sites up and running and struggling with patient enrollment... they currently have less than 5 patients enrolled (out of a target 60)... the trial will last until at least the end of 2028 (later if they can't get enrollment to pick up) - that is CYDY's estimate... after that, it will take them at least a year to submit to the FDA... so you are looking at mid 2030 best case scenario for an approval... and if you research CYDY, you will see they never hit best case scenario... Thorilium is a habitual liar... $ICU $BIVI

2 · Reply

Sensore Oct. 14 at 12:10 PM

$BIVI ..

0 · Reply

toccoc Oct. 14 at 7:25 AM

$BIVI go buyout

0 · Reply

Thorilium Oct. 14 at 3:27 AM

$ICU this is another stock set to spark 1,000% upon revenue news The adult AKI enrollment is especially to watch now because imo the delay will be not that longer than origanlly planned Race towards 1 is in particular exciting now, now it nears the SP of Cytodyn...and the market cap of ICU is more than 10 Times less with an approved divice and revenue streams. CYDY is however also nearing approval potential and will break out huge. Race towards 1 has hyper exciting! $CYDY $ICU $BIVI My three inflammation bets

0 · Reply

Sensore Oct. 10 at 9:32 PM

$BIVI ..

0 · Reply

_CircuitBreaker Oct. 9 at 10:36 PM

Keep a close watch on CMCT! ITS MOVING!! $BIVI $BGMS $WBX $SPRC __

0 · Reply

Thorilium Oct. 9 at 7:30 AM

$BIVI so march is the timing to look at this again, Will do nothing but go up and down

0 · Reply

Stmkr Oct. 9 at 7:23 AM

$BIVI Pretty good setup here. Should run towards PD readout. PR on COVID-19 trial timelines expected within a month with a potential readout in mid-2026. So 2 big readouts within cash runway. Rest of the programs (AD, Ascites) paused for now. Focus is to make it through above 2 readouts. I suspect there wont be another offering at the least until the PD readout

0 · Reply

Thorilium Oct. 8 at 8:52 PM

At $ICU they have to look really well into $BIVI two Times a reverse is one time to much, it costs Money and shorts play with your stock until there are good results and than explodes over 1,000%

0 · Reply

Thorilium Oct. 8 at 8:36 PM

$CYDY how funny so this moves fake Down to go up again... Mazzy again in over time posting fake info Just same time at $BIVI and $ICU and many others

0 · Reply

Market Cap	14.17M
Revenue (ttm)	0.00
Net Income (ttm)	-17.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	128,900
Avg Vol	237,316
Day's Range	N/A - N/A
Shares Out	7.54M
Stochastic %K	27%
Beta	0.71
Analysts	Sell
Price Target	$12.00